• Pol II Degradation Triggers Cell Death Beyond Transcription

  2026-04-18

  This study demonstrates that targeted degradation of RNA polymerase II (Pol II) can activate cell death independently of transcriptional shutdown, revealing a previously unrecognized role for Pol II in cell survival. These findings have broad implications for DNA damage response research, especially in the context of DNA repair and apoptotic pathways.

• Modeling HSV-1 Latency in Human iPSC-Derived Sensory Neurons

  2026-04-17

  This study establishes a robust, scalable platform using human inducible pluripotent stem cell (hiPSC)-derived sensory neurons to model latent infection and reactivation of herpes simplex virus 1 (HSV-1). The work addresses a critical gap in neurovirology by enabling detailed mechanistic studies of HSV-1 latency and its neuronal reactivation in a human-relevant system.

• Clathrin-Mediated Entry of Grass Carp Reovirus: Inhibitor An

  2026-04-16

  Wang et al. (2018) established that the genotype III grass carp reovirus (GCRV104) enters host cells via clathrin-mediated, pH-dependent endocytosis, rather than actin-dependent pathways. Their comparative pharmacological inhibitor analysis delineates essential host factors for viral entry, refining the mechanistic understanding of aquareovirus infection and informing antiviral strategy development.

• Paclitaxel (Taxol): Optimizing Cancer Research Assays (SKU A

  2026-04-15

  This article addresses real laboratory challenges in cancer research, focusing on the practical integration of Paclitaxel (Taxol) (SKU A4393) for cell viability and cytotoxicity assays. Drawing from evidence-based protocols and vendor comparisons, it demonstrates how APExBIO’s formulation delivers reproducible, high-sensitivity results that empower advanced workflows across oncology applications.

• Auranofin as a Thioredoxin Reductase Inhibitor: Protocols an

  2026-04-14

  Auranofin is a gold-standard thioredoxin reductase inhibitor that unlocks new experimental dimensions in redox biology, apoptosis induction, and radiosensitization. This article translates breakthrough mechanistic research into actionable workflows, troubleshooting guidance, and advanced use-case strategies for cancer and infection models.

• Molnupiravir Blocks Bourbon Virus in Mice: Antiviral Efficac

  2026-04-13

  This study demonstrates that molnupiravir, a broad-spectrum antiviral, effectively inhibits Bourbon virus (BRBV) replication and disease progression in a lethal mouse model. The findings highlight the therapeutic potential of nucleoside analogues against emerging tick-borne RNA viruses and provide key protocol insights for antiviral research.

• RWJ 67657: Precision Inhibition in p38 MAP Kinase Pathway Re

  2026-04-13

  RWJ 67657 (JNJ-3026582) empowers researchers with selective, orally active inhibition of p38α/β MAP kinases, enabling reproducible cytokine regulation and advanced inflammatory disease modeling. Its dual-action mechanism and robust selectivity set a new benchmark for workflow reliability and translational insight.

• Foretinib (GSK1363089): Strategic Multikinase Inhibition in

  2026-04-12

  This thought-leadership article unpacks the mechanistic, experimental, and translational landscape of Foretinib (GSK1363089), a potent ATP-competitive multikinase inhibitor, for advanced cancer research. Emphasizing evidence-based insights, protocol guidance, and differentiated strategic recommendations, the article bridges foundational in vitro methodology with actionable translational strategy, positioning Foretinib as a next-generation tool for tumor growth and metastasis models. It contextualizes findings alongside the landmark dissertation by Schwartz (2022) and recent expert commentary, advancing the conversation beyond standard product descriptions to set a new bar for experimental rigor and translational vision.

• Firefly Luciferase mRNA: Optimized Workflows for Reliable As

  2026-04-12

  Firefly Luciferase mRNA (ARCA, 5mCTP, ΨUTP) delivers robust, low-immunogenicity bioluminescent reporting across gene expression, cell viability, and in vivo imaging assays. Discover actionable experimental workflows, troubleshooting strategies, and innovations that set this reporter apart for reproducible, high-sensitivity research.

• Dabigatran Etexilate: Direct Thrombin Inhibitor in Research

  2026-04-11

  Dabigatran etexilate sets the benchmark for direct thrombin inhibition, offering superior precision for anticoagulant and atrial fibrillation research. Discover streamlined protocols, advanced comparative workflows, and actionable troubleshooting tips for maximizing reproducibility with APExBIO’s gold-standard compound.

• Phosphatase Inhibitor Cocktail 1: Precision for Phosphorylat

  2026-04-11

  Phosphatase Inhibitor Cocktail 1 (100X in DMSO) from APExBIO empowers researchers to maintain protein phosphorylation with unmatched fidelity—enabling high-confidence phosphoproteomic workflows and advanced signaling analysis. Explore optimized protocols, troubleshooting strategies, and reference-driven innovations that set this alkaline phosphatase inhibitor apart.

• Foretinib (GSK1363089): ATP-Competitive Multikinase Inhib...

  2026-04-10

  Foretinib (GSK1363089) is a potent ATP-competitive VEGFR and HGFR/Met inhibitor used in cancer research to block tumor cell growth and metastasis. This dossier provides machine-readable, evidence-based insights into its mechanism, benchmarks, and workflow integration.

• Angiotensin III (human, mouse): Precision Tool for Cardio...

  2026-04-09

  Angiotensin III (human, mouse) stands out as a versatile RAAS peptide, enabling researchers to dissect aldosterone regulation, pressor activity, and receptor signaling with unmatched specificity. Its high purity, robust solubility, and validated performance make it indispensable for advanced cardiovascular and neuroendocrine disease modeling.

• GSK J4 HCl: Unraveling Epigenetic Crosstalk in Immune Reg...

  2026-04-08

  Explore how GSK J4 HCl, a potent H3K27 demethylase inhibitor, enables deeper investigation into chromatin remodeling and immune modulation. This article uniquely connects histone demethylation pathways with immune cell recruitment, providing advanced insights for epigenetic regulation research.

• Foretinib (GSK1363089): Mechanistic Mastery and Strategic...

  2026-04-08

  This thought-leadership article explores the mechanistic, experimental, and translational landscape of Foretinib (GSK1363089), a potent multikinase ATP-competitive inhibitor targeting VEGFR and HGFR/Met. Integrating rigorous evidence, workflow strategy, and competitive insight, we deliver actionable guidance for translational researchers seeking to unlock new frontiers in cancer therapeutics. Drawing from recent doctoral research and advanced in vitro modeling, we highlight how APExBIO’s Foretinib uniquely empowers the oncology research community.

14338 records 1/956 page Next 12345 下5页 Last page